Synthetic Biologics - SYN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)

This chart shows the closing price for SYN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Synthetic Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SYN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SYN

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Synthetic Biologics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for SYN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Synthetic Biologics. This rating has held steady since July 2023, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/2/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/20/2022Cantor FitzgeraldInitiated CoverageOverweight
3/17/2022Alliance Global PartnersBoost Target$12.50 ➝ $22.50
8/6/2021Maxim GroupInitiated CoverageBuy$25.00
3/12/2021Maxim GroupUpgradeHold ➝ Buy
10/2/2020Maxim GroupDowngradeBuy ➝ Hold
8/7/2020Maxim GroupInitiated CoverageBuy$15.00
6/18/2020Maxim GroupInitiated CoverageBuy$15.00
5/6/2020Alliance Global PartnersLower TargetBuy$22.50 ➝ $12.50
(Data available from 12/23/2019 forward)

News Sentiment Rating

0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/27/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/26/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/26/2024
  • 1 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/25/2024
  • 1 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/24/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/24/2024
  • 2 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
11/23/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/23/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Synthetic Biologics logo
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

57,700 shs

Average Volume

197,338 shs

Market Capitalization

$16.16 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.38

Frequently Asked Questions

What sell-side analysts currently cover shares of Synthetic Biologics?

The following Wall Street research analysts have issued reports on Synthetic Biologics in the last twelve months:
View the latest analyst ratings for SYN.

What is the current price target for Synthetic Biologics?

0 Wall Street analysts have set twelve-month price targets for Synthetic Biologics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Synthetic Biologics in the next year.
View the latest price targets for SYN.

What is the current consensus analyst rating for Synthetic Biologics?

Synthetic Biologics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for SYN.

What other companies compete with Synthetic Biologics?

How do I contact Synthetic Biologics' investor relations team?

Synthetic Biologics' physical mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company's listed phone number is (301) 417-4364 and its investor relations email address is [email protected]. The official website for Synthetic Biologics is www.syntheticbiologics.com. Learn More about contacing Synthetic Biologics investor relations.